Our investments.
Creating value. Impacting lives.
Portfolio.
We are currently invested in the following innovative companies. Each of them are bringing potentially life-changing products to the market.
Lubris BioPharma is a biopharmaceutical company based in Weston, Massachusetts, developing recombinant human lubricant for the treatment of dry eye, osteoarthritis and other age & inflammation-related conditions.
Nacuity Pharmaceuticals, Inc. is a biopharmaceutical company that has acquired certain rights to, and is developing, NACA, a small molecule antioxidant for the treatment of retinitis pigmentosa and potentially other retinal-based diseases.
Jupiter Neurosciences, Inc. (JOT) is a clinical stage specialty pharmaceutical company developing therapies for rare diseases linked to single gene deficiencies. JOT has developed a unique formula, JOTROL™, which is a unique formulation of Resveratrol.
Inversago Pharma Inc. is focused on the development of peripherally-restricted CB1 receptor (CB1) inverse agonists for the treatment of Prader-Willi syndrome, type 1 diabetes and metabolic disorders in general.
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed, in the United States.
Azora Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecule new chemical entities for the treatment of autoimmune, inflammatory diseases. Our team has decades of experience in drug development and has helped develop groundbreaking medicines for patients, including Uceris®, Tysabri®, Ycanth® and Humira®.
Prevatex is developing science based probiotics for mothers and infants.
Prevatex will bring to market the next generation of probiotic-based biotherapeutics to establish, restore, and maintain a healthy maternal microbiome during pregnancy, and minimize the risk of food allergy in their infants.